Asset Details
Do you wish to reserve the book?
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Do you wish to request the book?
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
2013
Overview
A number of agents are now approved for the treatment of renal cancer. A comparison of two agents, pazopanib and sunitinib, showed similar levels of antitumor activity but distinct side-effect profiles. Symptoms affecting quality of life were somewhat worse with sunitinib.
Renal-cell carcinoma is the most common kidney cancer.
1
Up to 30% of patients have metastases at the time of the initial diagnosis.
2
Systemic treatment for patients who have metastatic renal-cell carcinoma with a clear-cell histologic component has shifted from cytokines to drugs targeting angiogenesis. Sunitinib, pazopanib, and five other agents have been approved by the Food and Drug Administration for the treatment of clear-cell, metastatic renal-cell carcinoma.
3
,
4
Among the tyrosine kinase inhibitors, pazopanib and sunitinib are first-line treatment options.
Sunitinib has been compared with interferon alfa in patients who had not previously received systemic therapy for renal-cell carcinoma,
5
whereas . . .
Publisher
Massachusetts Medical Society
Subject
/ Alanine
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Biological and medical sciences
/ Cancer
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - secondary
/ Clear cell-type renal cell carcinoma
/ Fatigue
/ Feet
/ Female
/ Humans
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - pathology
/ Kidneys
/ Male
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Nephrology. Urinary tract diseases
/ Patients
/ Pharynx
/ Pyrimidines - adverse effects
/ Pyrimidines - therapeutic use
/ Safety
/ Sulfonamides - adverse effects
/ Sulfonamides - therapeutic use
/ Tumors
